| Preview | Issue Date | Title | Author(s) |
| 2019 | Aminoguanidines: new leads for treatment of Giardia duodenalis infection | Abraham, R.J.; Abraham, S.; Stevens, A.J.; Page, S.W.; McCluskey, A.; Trott, D.J.; O'Handley, R.M. |
| 2022 | Antigiardial activity of novel guanidine compounds | Stevens, A.J.; Abraham, R.; Young, K.A.; Russell, C.C.; McCluskey, S.N.; Baker, J.R.; Rusdi, B.; Page, S.W.; O'Handley, R.; O'Dea, M.; Abraham, S.; McCluskey, A. |
| 2020 | Antimicrobial use and stewardship practices on Australian beef feedlots | Badger, S.M.; Sullivan, K.F.; Jordan, D.; Caraguel, C.; Page, S.W.; Cusack, P.; Frith, D.; Trott, D.J. |
| 2019 | Biofilm production by pathogens associated with canine otitis externa, and the antibiofilm activity of ionophores and antimicrobial adjuvants | Chan, W.Y.; Hickey, E.E.; Page, S.W.; Trott, D.J.; Hill, P.B. |
| 2019 | Discovery of 4,6-bis(2-((E)-benzylidene)hydrazinyl)pyrimidin-2-Amine with antibiotic activity | Russell, C.C.; Stevens, A.; Young, K.A.; Baker, J.R.; McCluskey, S.N.; Khazandi, M.; Pi, H.; Ogunniyi, A.; Page, S.W.; Trott, D.J.; McCluskey, A. |
| 2018 | Gram-positive and gram-negative antibiotic activity of asymmetric and monomeric robenidine analogues | Russell, C.C.; Stevens, A.; Pi, H.; Khazandi, M.; Ogunniyi, A.; Young, K.A.; Baker, J.R.; McCluskey, S.N.; Page, S.W.; Trott, D.J.; McCluskey, A. |
| 2022 | Impact of a novel anticoccidial analogue on systemic staphylococcus aureus infection in a bioluminescent mouse model | Nguyen, H.T.; Venter, H.; Woolford, L.; Young, K.; McCluskey, A.; Garg, S.; Page, S.W.; Trott, D.J.; Ogunniyi, A.D. |
| 2022 | In Vitro Activity of Robenidine Analogues NCL259 and NCL265 against Gram-Negative Pathogens | Pi, H.; Venter, H.; Russell, C.C.; Young, K.A.; McCluskey, A.; Page, S.W.; Ogunniyi, A.D.; Trott, D.J. |
| 2019 | In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa | Chan, W.Y.; Hickey, E.E.; Khazandi, M.; Page, S.W.; Trott, D.J.; Hill, P.B. |
| 2019 | In vitro antimicrobial activity of robenidine, ethylenediaminetetraacetic acid and polymyxin B nonapeptide against important human and veterinary pathogens | Khazandi, M.; Pi, H.; Chan, W.Y.; Ogunniyi, A.D.; Sim, J.X.F.; Venter, H.; Garg, S.; Page, S.W.; Hill, P.B.; McCluskey, A.; Trott, D.J. |
| 2019 | In vitro antimicrobial activity of seven adjuvants against common pathogens associated with canine otitis externa | Chan, W.Y.; Khazandi, M.; Hickey, E.E.; Page, S.W.; Trott, D.J.; Hill, P.B. |
| 2020 | In vitro efficacy and pharmacodynamic profiles of four polyether ionophores against methicillin-resistant Staphylococcus spp. | Hickey, E.E.; Page, S.W.; Trott, D.J. |
| 2023 | Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces Staphylococcus aureus infection and reduces Escherichia coli infection in combination with sub-inhibitory colistin concentrations in a bioluminescent mouse model | Nguyen, H.T.; Venter, H.; Woolford, L.; Young, K.A.; McCluskey, A.; Garg, S.; Sapula, S.S.; Page, S.W.; Ogunniyi, A.; Trott, D.J.; Leggett, J.E. |
| 2021 | Repurposing of the fasciolicide triclabendazole to treat infections caused by staphylococcus spp. and vancomycin-resistant enterococci | Pi, H.; Ogunniyi, A.D.; Savaliya, B.; Nguyen, H.T.; Page, S.W.; Lacey, E.; Venter, H.; Trott, D.J. |
| 2021 | Semisynthesis and biological evaluation of a focused library of unguinol derivatives as next-generation antibiotics | Morshed, M.T.; Nguyen, H.T.; Vuong, D.; Crombie, A.; Lacey, E.; Ogunniyi, A.D.; Page, S.W.; Trott, D.J.; Piggott, A.M. |
